News | September 16, 2025
Biocartis receives FDA approval for Idylla CDx MSI test
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Subscribe To Our Newsletter & Stay Updated
